Before taking Ibrance(palbociclib)

Important safety information for prescribers and patients.

Warnings and Considerations

Key precautions include the need for frequent monitoring of complete blood counts due to the risk of severe neutropenia. Patients should be monitored for pulmonary symptoms indicative of interstitial lung disease (ILD)/pneumonitis, and IBRANCE should be permanently discontinued if severe ILD occurs. Due to the risk of embryo-fetal toxicity, females of reproductive potential must use effective contraception during treatment and for several weeks after the last dose. Concomitant use with strong CYP3A inhibitors or inducers should be avoided.